Zelda

Zelira Therapeutics is an Australia-based cannabinoid biopharmaceutical company developing and commercializing clinically validated cannabinoid-based medicines and consumer health products. The company focuses its prescription portfolio on autism spectrum disorder, insomnia, chronic non-cancer pain, and diabetic nerve pain, while also marketing OTC dermatology and oral-care products in selected markets. Zelira, formerly known as Zelda Therapeutics, merged with Ilera Therapeutics and now operates across Australia, the United States, the United Kingdom, and Europe. Its lead regulatory program is HOPE for autism spectrum disorder, which has progressed through FDA pre-IND interactions and is being advanced through a dedicated SPV structure. The company remains active, though its ASX-listed shares were suspended from quotation in March 2026.